Boston Scientific price target raised to $58 from $56 at RBC Capital

RBC Capital raised the firm’s price target on Boston Scientific to $58 from $56 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 results for Medical Devices. The analyst is bullish on the set-up for the group, noting that companies should benefit from higher healthcare utilization as staffing is increasingly less of a limiting factor. The overall sentiment for Boston Scientific is also positive into the second half of 2023 and 2024 given its portfolio exposure, significant growth catalysts, and potential for margin expansion, the firm tells investors in a research note.